On September 3, 2024 Imugene Limited (ASX:IMU), a clinical-stage immuno‐ oncology company, reported that it will hold an investor webinar on Wednesday 4 September 2024 at 10am AEST to discuss the new data from its azer-cel Phase 1b clinical trial in blood cancer Diffuse Large B-Cell Lymphoma (announced 2 September 2024) (Press release, Imugene, SEP 3, 2024, https://mcusercontent.com/e38c43331936a9627acb6427c/files/2d4fea36-e0fc-fc96-87d4-f6aa75112df8/Imugene_Webinar_Azer_cel_Trial_Update.pdf [SID1234646269]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presenting as part of the webinar will be Imugene’s Managing Director and CEO Leslie Chong, alongside Chief Medical Officer Dr Paul Woodard.
Shareholders, investors and other interested parties are encouraged to register for the webinar at the following link:
After registering, you will receive a confirmation email with details on how to join the webinar. A recording will be available at the same link shortly after the conclusion of the session.